Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 2, Issue 10, 2007, Pages 927-932

  Hirsh, Vera ^a,c   Soulieres, Denis ^b   Duclos, Marie ^a   Faria, Sergio ^a   Del Vecchio, Pierre ^b   Ofiara, Linda ^a   Ayoub, Jean Pierre ^b   Charpentier, Danielle ^b   Gruber, James ^a   Portelance, Lorraine ^a   Souhami, Luis ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Carboplatin gemcitabine induction; Concomitant radiochemotherapy; Lung cancer; Neoadjuvant chemotherapy; Stage IIIA B non small cell lung cancer

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; GEMCITABINE; PACLITAXEL;

ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG TOLERABILITY; ESOPHAGITIS; ESOPHAGUS FISTULA; FEMALE; HUMAN; INFECTION; INOPERABLE CANCER; INTERSTITIAL PNEUMONIA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SKIN MANIFESTATION; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; PROSPECTIVE STUDIES; RADIOTHERAPY DOSAGE; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34848858993     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181560b92     Document Type: Article

References (36)

1. American Cancer Society. Cancer Facts and Figures 2002. Atlanta: American Cancer Society, 2002.
2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-543.
3. Vokes EE, Herndon JE, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage III B non-small cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol 2002;20:4191-4198.
4. van Zandwijk N, Kramer GWP, Schramel S, et al. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage III A N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of lung cancer cooperative group (EORTC 08955). J Clin Oncol 2000;18:2658-2664.
5. Dillman RO, Seagren SL, Propert KJ, et al. Improved survival in stage III non-small cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-1215.
6. Le Chevalier T, Arriagada R, Tarayre M, et al. Significant effect of adjuvant chemotherapy on survival on locally advanced non-small cell lung carcinoma. J Natl Cancer Inst 1992;84:58-59.
7. Mattson K, Holsti LR, Holsti P, et al. Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol 1988;24:477-482.
8. Morton RF, Jett JR, McGinnis WL, et al. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. Ann Intern Med 1991;115:681-686.
9. Cullen MH, Ferry D, Souhami R, et al. A randomized trial of chemotherapy plus radiotherapy versus radiotherapy alone in localized non-small cell lung cancer. Lung Cancer 1991;7(Suppl):Abstract 613.
10. Miller TP, Crowley JJ, Mira J, et al. A randomized trial of chemotherapy and radiotherapy for stage III non-small cell lung cancer. Cancer Ther 1998;1:229-236.
11. Cox JD, Azarnia N, Byhardt RW, et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses to 60.0 Gy to 79.2 Gy: Possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with RTOG stage III non-small cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 1990;8:1543-1555.
12. Rowell NP, O'Rourke NP. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2004;18:CD002140.
13. Fournel P, Thomas P, Souquet PJ, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 study. J Clin Oncol 2006;23:5910-5917.
14. Curran WJ, Scott C, Langer C, et al. Phase III comparison of sequential versus concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer (NSCLC): Report of Radiation Therapy Oncology Group (RTOG) 9410. J Clin Oncol 2007 (in press).
15. Furuse K, Fukuoka M, Takada H, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non small cell lung cancer. J Clin Oncol 1999;17:2692-2699.
16. Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005;23:5883-5891.
17. Choy H, Safran H. Preliminary analysis of a phase II study of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Semin Oncol 1995;22(Suppl 9):55-57.
18. Choy H, Akerley W, Safran H, et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small cell lung cancer. J Clin Oncol 1994;12:2682-2686.
19. Choy H, Browne MJ. Paclitaxel as a radiation sensitizer in non-small cell lung cancer. Semin Oncol 1995;22(Suppl 6):70-74.
20. Vokes EE, Leopald KA, Herndon JE, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage III B non-small cell lung cancer: Cancer and Leukemia Group B Study 9431. J Clin Oncol 2002;20:4191-4198.
21. Gonzalez E, Sanchez-Rovira P, Jaen A, et al. Phase I study concomitant gemcitabine (G) with radiotherapy (RT) in stage III NSCLC. Eur J Can 1999;35(Suppl 4):Abstract 1054A.
22. Trodella L, Granone P, Valente S, et al. Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non small cell lung cancer. J Clin Oncol 2002;20:804-810.
23. Athanasious E, Cyrgias G, Boinis K, et al. Concurrent chemoradiotherapy with gemcitabine for locally advanced non-small cell lung cancer (NSCLC): preliminary results of a phase II study (abstract). Ann Oncol 1998;9(Suppl 4).
24. van Putten JWG, Price A, van der Leest AHD, et al. A phase I study of gemcitabine with concurrent radiotherapy in stage III locally advanced non-small cell lung cancer. Clin Cancer Res 2003;9:2472-2477.
25. Blackstock AW, Ho C, Butler J, et al. Phase Ia/Ib chemoradiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage IIIA/B non small cell lung cancer. J Thorac Oncol 2006;5:434-440.
26. Zwitter M, Kovac V, Smrdel U, et al. Gemcitabine, cisplatin and hyperfractionated accelerated radiotherapy for locally advanced nonsmall cell lung cancer. J Thorac Oncol 2006;1:662-666.
27. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:15-24.
28. Zatloukal M, Kolek J, Skrickova M, et al. Gemcitabine plus cisplatin vs gemcitabine plus carboplatin in stage III b and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 2003;41:321-331.
29. Rudd RM, Gower NH, Spiro SG, et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage III B or IV non-small cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 2005;23:142-153.
30. Sederholm C, Hillerdal G, Lamberg K, et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non small cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol 2005;23:8380-8388.
31. Kudrik FJ, Rivera MP, Molina PL, et al. Hypersensitivity pneumonitis in advanced non small cell lung cancer patients receiving gemcitabine and paclitaxel: report of two cases and a review of literature. Clin Lung Cancer 2002;4:52-56.
32. Vokes EE, Hendron JE, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared to chemotherapy alone for regionally advanced unresectable stage II non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007;25:1698-1704.
33. Huber RM, Flentje M, Schimdt M, et al. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT 99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol 2006;24:4397-4403.
34. Aerts JG, Surmont V, van Klaveren RJ, et al. A phase II study of induction therapy with carboplatin and gemcitabine among patients with locally-advanced non-small cell lung cancer. J Thorac Oncol 2006;1:532-536.
35. Hirsh V, Whittom R, Ofiara L, et al. Weekly paclitaxel and gemcitabine chemotherapy for metastatic non small cell lung carcinoma (NSCLC): a dose-optimizing phase II trial. Cancer 2003;97:2242-2247.
36. Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non small cell lung cancer: a phase III randomized trial. J Clin Oncol 2002;20:3578-3585.